Literature DB >> 17335633

Clinical surveillance of thrombotic microangiopathies in Scotland, 2003-2005.

K G J Pollock1, D Young, T J Beattie, W T A Todd.   

Abstract

The prevalence, incidence and outcomes of haemolytic uraemic syndrome (HUS) and thrombotic thrombocytopaenic purpura (TTP) are not well established in adults or children from prospective studies. We sought to identify both outcomes and current management strategies using prospective, national surveillance of HUS and TTP, from 2003 to 2005 inclusive. We also investigated the links between these disorders and factors implicated in the aetiology of HUS and TTP including infections, chemotherapy, and immunosuppression. Most cases of HUS were caused by verocytotoxin-producing Escherichia coli (VTEC), of which serotype O157 predominated, although other serotypes were identified. The list of predisposing factors for TTP was more varied although use of immunosuppressive agents and severe sepsis, were the most frequent precipitants. The study demonstrates that while differentiating between HUS and TTP is sometimes difficult, in most cases the two syndromes have quite different predisposing factors and clinical parameters, enabling clinical and epidemiological profiling for these disorders.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17335633      PMCID: PMC2870767          DOI: 10.1017/S0950268807008217

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  24 in total

1.  von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in Escherichia coli O157:H7-associated hemolytic uremic syndrome.

Authors:  H M Tsai; W L Chandler; R Sarode; R Hoffman; S Jelacic; R L Habeeb; S L Watkins; C S Wong; G D Williams; P I Tarr
Journal:  Pediatr Res       Date:  2001-05       Impact factor: 3.756

2.  The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections.

Authors:  C S Wong; S Jelacic; R L Habeeb; S L Watkins; P I Tarr
Journal:  N Engl J Med       Date:  2000-06-29       Impact factor: 91.245

Review 3.  Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome.

Authors:  Phillip I Tarr; Carrie A Gordon; Wayne L Chandler
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

4.  Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura.

Authors:  G G Levy; W C Nichols; E C Lian; T Foroud; J N McClintick; B M McGee; A Y Yang; D R Siemieniak; K R Stark; R Gruppo; R Sarode; S B Shurin; V Chandrasekaran; S P Stabler; H Sabio; E E Bouhassira; J D Upshaw; D Ginsburg; H M Tsai
Journal:  Nature       Date:  2001-10-04       Impact factor: 49.962

5.  Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.

Authors:  H M Tsai; E C Lian
Journal:  N Engl J Med       Date:  1998-11-26       Impact factor: 91.245

Review 6.  Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression.

Authors:  Amit X Garg; Rita S Suri; Nick Barrowman; Faisal Rehman; Doug Matsell; M Patricia Rosas-Arellano; Marina Salvadori; R Brian Haynes; William F Clark
Journal:  JAMA       Date:  2003-09-10       Impact factor: 56.272

7.  Clopidogrel-associated TTP: an update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the Food and Drug Administration.

Authors:  Anaadriana Zakarija; Nicholas Bandarenko; Dilip K Pandey; Amy Auerbach; Dennis W Raisch; Benjamin Kim; Hau C Kwaan; June M McKoy; Brian P Schmitt; Charles J Davidson; Paul R Yarnold; Philip B Gorelick; Charles L Bennett
Journal:  Stroke       Date:  2004-01-05       Impact factor: 7.914

Review 8.  Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities. A review of 56 autopsy cases.

Authors:  Gregory A Hosler; Ana M Cusumano; Grover M Hutchins
Journal:  Arch Pathol Lab Med       Date:  2003-07       Impact factor: 5.534

9.  ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients.

Authors:  Sara K Vesely; James N George; Bernhard Lämmle; Jan-Dirk Studt; Lorenzo Alberio; Mayez A El-Harake; Gary E Raskob
Journal:  Blood       Date:  2003-03-13       Impact factor: 22.113

Review 10.  Acute kidney failure: a pediatric experience over 20 years.

Authors:  Debra M Williams; Sue S Sreedhar; John J Mickell; James C M Chan
Journal:  Arch Pediatr Adolesc Med       Date:  2002-09
View more
  8 in total

1.  Infection in Patients with Suspected Thrombotic Microangiopathy Based on Clinical Presentation.

Authors:  Benjamin Thoreau; Florent von Tokarski; Adeline Bauvois; Guillaume Bayer; Christelle Barbet; Sylvie Cloarec; Elodie Mérieau; Sébastien Lachot; Denis Garot; Louis Bernard; Emmanuel Gyan; Franck Perrotin; Claire Pouplard; François Maillot; Philippe Gatault; Bénédicte Sautenet; Emmanuel Rusch; Véronique Frémeaux-Bacchi; Cécile Vigneau; Fadi Fakhouri; Jean-Michel Halimi
Journal:  Clin J Am Soc Nephrol       Date:  2021-09       Impact factor: 10.614

2.  Multilocus genotype analysis of Escherichia coli O157 isolates from Australia and the United States provides evidence of geographic divergence.

Authors:  Glen E Mellor; Thomas E Besser; Margaret A Davis; Brittany Beavis; Wookyung Jung; Helen V Smith; Amy V Jennison; Christine J Doyle; P Scott Chandry; Kari S Gobius; Narelle Fegan
Journal:  Appl Environ Microbiol       Date:  2013-06-14       Impact factor: 4.792

3.  Sorbitol-fermenting Escherichia coli O157, Scotland.

Authors:  Kevin G J Pollock; Mary E Locking; T James Beattie; Heather Maxwell; Ian Ramage; David Hughes; Jennifer Cowieson; Lesley Allison; Mary Hanson; John M Cowden
Journal:  Emerg Infect Dis       Date:  2010-05       Impact factor: 6.883

4.  Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome.

Authors:  Maro Ohanian; Christian Cable; Kathleen Halka
Journal:  Clin Pharmacol       Date:  2011-05-24

5.  Highly virulent Escherichia coli O26, Scotland.

Authors:  Kevin G J Pollock; Sheetal Bhojani; T James Beattie; Lesley Allison; Mary Hanson; Mary E Locking; John M Cowden
Journal:  Emerg Infect Dis       Date:  2011-09       Impact factor: 6.883

6.  Saltelli Global Sensitivity Analysis and Simulation Modelling to Identify Intervention Strategies to Reduce the Prevalence of Escherichia coli O157 Contaminated Beef Carcasses.

Authors:  Victoria J Brookes; David Jordan; Stephen Davis; Michael P Ward; Jane Heller
Journal:  PLoS One       Date:  2015-12-29       Impact factor: 3.240

7.  Temporal and spatial patterns of bovine Escherichia coli O157 prevalence and comparison of temporal changes in the patterns of phage types associated with bovine shedding and human E. coli O157 cases in Scotland between 1998-2000 and 2002-2004.

Authors:  Michael C Pearce; Margo E Chase-Topping; Iain J McKendrick; Dominic J Mellor; Mary E Locking; Lesley Allison; Helen E Ternent; Louise Matthews; Hazel I Knight; Alastair W Smith; Barti A Synge; William Reilly; J Christopher Low; Stuart W J Reid; George J Gunn; Mark E J Woolhouse
Journal:  BMC Microbiol       Date:  2009-12-29       Impact factor: 3.605

8.  Outbreak of haemolytic uraemic syndrome in Norway caused by stx2-positive Escherichia coli O103:H25 traced to cured mutton sausages.

Authors:  Barbara Schimmer; Karin Nygard; Hanne-Merete Eriksen; Jørgen Lassen; Bjørn-Arne Lindstedt; Lin T Brandal; Georg Kapperud; Preben Aavitsland
Journal:  BMC Infect Dis       Date:  2008-04-03       Impact factor: 3.090

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.